Biotech entity
All 2 tracked stories fall under one category: clinical-trial. Of the tracked stories, 1 of 2 also mention Bayer, the most common co-covered peer. The tracked stories average 6.5 original sources each. HMI-115 appears in 2 tracked Biotech stories from March 25, 2026.
Last mentioned: Mar 25, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
All 2 tracked stories fall under one category: clinical-trial. Of the tracked stories, 1 of 2 also mention Bayer, the most common co-covered peer. The tracked stories average 6.5 original sources each. HMI-115 appears in 2 tracked Biotech stories from March 25, 2026.
Computed from the 2 stories linked to this entity, with beat comparisons drawn from all 17 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering HMI-115. Shared-story counts are live from our verified record — not editorial picks.
Phase III Initiation
First patient dosed in the pivotal Phase III clinical trial for endometriosis.
Regulatory Designations
HMI-115 receives FDA Fast Track and NMPA Breakthrough Therapy designations.
Trial Expansion
Continued enrollment across global multicenter sites for the 24-week study.
Phase II Completion
Global multicenter Phase II trial results published in The Lancet showing efficacy and safety.
Phase II Completion
Positive results from Phase II studies demonstrate pain reduction and safety.
Licensing Agreement
Hope Medicine acquires global rights for HMI-115 from Bayer.
Hope Medicine Inc. has initiated dosing in its Phase III clinical trial for HMI-115, a first-in-class non-hormonal monoclonal antibody for endometriosis. This milestone marks the first time a non-hormonal treatment for this condition has reached Phase III development globally, offering a potential alternative to traditional hormonal therapies.
Hope Medicine has officially initiated its Phase III clinical trial for endometriosis, dosing the first patient with HMI-115. This milestone marks a significant advancement in the development of a first-in-class prolactin receptor antagonist designed to address the high unmet need in women's health.
HMI-115 is linked from 2 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
